VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AD/PD 2021 | Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, Expert Medical Director, Group Leader, Chair of Medical Directors Fellows at Roche Pharma Research and Early Development (pRED) and Researcher at King’s College London, discusses prasinezumab, a humanized monoclonal antibody targeting alpha-synuclein. Prasinezumab has been reported to show an effect on multiple in vivo and cellular endpoints, particularly reducing the accumulation of alpha-synuclein aggregates, protecting neurons and synapses, and blocking α-synuclein propagation from cell to cell. In animal models, it was able to improve motor and cognitive behavior. These preclinical findings suggest that prasinezumab has the potential to slow down disease progression in Parkinson’s disease. The antibody is currently being investigated in Phase II clinical trials. This interview took place during the AD/PD™ 2021 conference.

Disclosures

G.Pagano is a full-time employee and shareholder of F. Hoffmann-La Roche Ltd